Inhibitory effects of evodiamine on the growth of human prostate cancer cell line LNCaP

International Journal of Cancer

Volumn 110, Issue 5, 2004, Pages 641-651

  Kan, Shu Fen ^a   Huang, William J ^a,b   Lin, Lie Chwen ^c   Wang, Paulus S ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c NATIONAL RESEARCH INSTITUTE OF CHINESE MEDICINE   (Taiwan)

Author keywords

Apoptosis; Cell growth; Evodiamine; G2 M arrest; Prostate cancer

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CASPASE 9; CYCLIN B1; EVODIAMINE; HERBACEOUS AGENT; LACTATE DEHYDROGENASE; PROTEIN KINASE;

ANDROGEN RELEASE; APOPTOSIS; ARTICLE; CANCER MORTALITY; CELL CYCLE; CELL CYCLE G2 PHASE; CELL DEATH; CELL PROLIFERATION; CHINESE MEDICINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG ISOLATION; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MITOSIS INHIBITION; NICK END LABELING; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CASPASES; CDC2 PROTEIN KINASE; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; COLORING AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; G2 PHASE; HISTONES; HUMANS; IN SITU NICK-END LABELING; L-LACTATE DEHYDROGENASE; MALE; MITOSIS; MODELS, CHEMICAL; PLANT EXTRACTS; PLOIDIES; PROSTATIC NEOPLASMS; QUINAZOLINES; TETRAZOLIUM SALTS; THIAZOLES; TIME FACTORS;

EID: 2942554803     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20138     Document Type: Article

References (50)

1. Hsing AW. Essential fatty acids and prostate cancer: an emerging hypothesis? Cancer Epidemiol Biomarkers Prev 1996;5:859-60.
2. Godley PA, Campbell MK, Gallagher P, Martinson FE, Mohler JL, Sandler RS. Biomarkers of essential fatty acid consumption and risk of prostatic carcinoma. Cancer Epidemiol Biomarkers Prev 1996;5:889-95.
3. Chang CK, Yu HJ, Chan KW, Lai MK. Secular trend and age-period-cohort analysis of prostate cancer mortality in Taiwan. J Urol 1997;158:1845-8.
4. Ross RK, Henderson BE. Do diet and androgens alter prostate cancer risk via a common etiologic pathway? J Natl Cancer Inst 1994;86:252-4.
5. Yeap BB, Krueger RG, Leedman PJ. Differential posttranscriptional regulation of androgen receptor gene expression by androgen in prostate and breast cancer cells. Endocrinology 1999;140:3282-91.
6. Ahmann FR, Citrin DL, deHaan HA, Guinan P, Jordan VC, Kreis W, Scott M, Trump, DL. Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer. J Clin Oncol 1987;5:912-7.
7. Grayhack JT, Keeler TC, Kozlowski JM. Carcinoma of the prostate: hormonal therapy. Cancer 1987;60:589-601.
8. Debruyne FM, Fernandez del Moral P, Geboers AD. LHRH-analogues therapy for metastatic prostate cancer. Prog Clin Biol Res 1988;260:27-39.
9. Dowsett M, Harris AL, Stuart-Harris R, Hill M, Cantwell BM, Smith IE, Jeffcoate SL. A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients. Br J Cancer 1985;52:525-9.
10. Paisey RB, Kadow C, Bolton C, Hartog M, Gingell JC. Effects of cyproterone acetate and a long-acting LHRH analogue on serum lipoproteins in patients with carcinoma of the prostate. J R Soc Med 1986;79:210-1.
11. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989;321:419-24.
12. Zi X, Grasso AW, Kung HJ, Agarwal R. A flavonoid antioxidant, silymarin, inhibits activation of erbB1 signaling and induces cyclin-dependent kinase inhibitors, G1 arrest, and anticarcinogenic effects in human prostate carcinoma DU145 cells. Cancer Res 1998;58:1920-9.
13. Zi X, Agarwal R. Silibinin decreases prostate-specific antigen with cell growth inhibition via G1 arrest, leading to differentiation of prostate carcinoma cells: implications for prostate cancer intervention. Proc Natl Acad Sci U S A 1999;96:7490-5.
14. Panaro NJ, Popescu NC, Harris SR, Thorgeirsson UP. Flavone acetic acid induces a G2/M cell cycle arrest in mammary carcinoma cells. Br J Cancer 1999;80:1905-11.
15. Boone CW, Kelloff GJ, Malone WE. Identification of candidate cancer chemopreventive agents and their evaluation in animal models and human clinical trials: a review. Cancer Res 1990;50:2-9.
16. Kelloff GJ, Boone CW, Crowell JA, Steele VE, Lubet R, Sigman CC. Chemopreventive drug development: perspectives and progress. Cancer Epidemiol Biomarkers Prev 1994;3:85-98.
17. Boone CW, Wattenberg LW. Current strategies of cancer chemoprevention: 13th Sapporo cancer seminar. Cancer Res 1994;54:3315-8.
18. Ames BN, Gold LS, Willett WC. The causes and prevention of cancer. Proc Natl Acad Sci U S A 1995;92:5258-65.
19. Yeh JY, Huang WJ, Kan SF, Wang PS. Inhibitory effects of digitalis on the proliferation of androgen dependent and independent prostate cancer cells. J Urol 2001;166:1937-42.
20. Yeh JY, Huang WJ, Kan SF, Wang PS. Effects of bufalin and cinobufagin on the proliferation of androgen dependent and independent prostate cancer cells. Prostate 2003;54:112-24.
21. Yamahara J, Yamada T, Kitani T, Naitoh Y, Fujimura H. Antianoxic action of evodiamine, an alkaloid in Evodia rutaecarpa fruit. J Ethnopharmacol 1989;27:185-92.
22. Chiou WF, Chou CJ, Shum AY, Chen CF. The vasorelaxant effect of evodiamine in rat isolated mesenteric arteries: mode of action. Eur J Pharmacol 1992;215:277-83.
23. Tsai TH, Lee TF, Chen CF, Wang LC. Thermoregulatory effects of alkaloids isolated from Wu-chu-yu in afebrile and febrile rats. Pharmacol Biochem Behav 1995;50:293-8.
24. Chiou WF, Sung YJ, Liao JF, Shum AY, Chen CF. Inhibitory effect of dehydroevodiamine and evodiamine on nitric oxide production in cultured murine macrophages. J Nat Prod 1997;60:708-11.
25. Lin H, Tsai SC, Chen JJ, Chiao YC, Wang SW, Wang GJ, Chen CF, Wang PS. Effects of evodiamine on the secretion of testosterone in rat testicular interstitial cells. Metabolism 1999;48:1532-5.
26. Yang LM CC, Lee KH. Synthesis of rutaecarpine and cytotoxic analogues. Bioorg Med Chem Lett 1995;5:465-8.
27. Ogasawara M, Matsubara T, Suzuki H. Screening of natural compounds for inhibitory activity on colon cancer cell migration. Biol Pharmacol Bull 2001;24:720-3.
28. Ogasawara M, Matsubara T, Suzuki H. Inhibitory effects of evodiamine on in vitro invasion and experimental lung metastasis of murine colon cancer cells. Biol Pharmacol Bull 2001;24:917-20.
29. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF. Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer 1978;21:274-81.
30. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979;17:16-23.
31. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP. LNCaP model of human prostatic carcinoma. Cancer Res 1983;43:1809-18.
32. Chung TD, Yu JJ, Spiotto MT, Bartkowski M, Simons JW. Characterization of the role of IL-6 in the progression of prostate cancer. Prostate 1999;38:199-207.
33. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
34. Steel RGD TJ. Principles and procedures of statistics. New York: McGraw-Hill, 1960.
35. Hung PH, Lin LC, Wang GJ, Chen CF, Wang PS, Inhibitory effect of evodiamine on aldosterone release by Zona glomerulosa cells in male rats. Chin J Physiol 2001;44:53-7.
36. Chiou WF, Chen CF. Pharmacological profile of evodiamine in isolated rabbit corpus cavernosum. Eur J Pharmacol 2002;446:151-9.
37. Draetta G. Cell cycle control in eukaryotes: molecular mechanisms of cdc2 activation. Trends Biochem Sci 1990;15:378-83.
38. Reddy GP. Cell cycle: regulatory events in G1→S transition of mammalian cells. J Cell Biochem 1994;54:379-86.
39. Pines J. Cyclins, CDKs and cancer. Semin Cancer Biol 1995;6:63-72.
40. Glotzer M, Murray AW, Kirschner MW. Cyclin is degraded by the ubiquitin pathway. Nature 1991;349:132-8.
41. Ling YH, Consoli U, Tornos C, Andreeff M, Perez-Soler R. Accumulation of cyclin B1, activation of cyclin B1-dependent kinase and induction of programmed cell death in human epidermoid carcinoma KB cells treated with taxol. Int J Cancer 1998;75:925-32.
42. Ling YH, Jiang JD, Holland JF, Perez-Soler R. Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines. Mol Pharmacol 2002;62:529-38.
43. Donaldson KL, Goolsby GL, Kiener PA, Wahl AF. Activation of p34cdc2 coincident with taxol-induced apoptosis. Cell Growth Differ 1994;5:1041-50.
44. Shi L, Nishioka WK, Th'ng J, Bradbury EM, Litchfield DW, Greenberg AH. Premature p34cdc2 activation required for apoptosis. Science 1994;263:1143-5.
45. Shi Y. A structural view of mitochondria-mediated apoptosis. Nat Struct Biol 2001;8:394-401.
46. Ranger AM, Malynn BA, Korsmeyer SJ. Mouse models of cell death. Nat Genet 2001;28:113-8.
47. Budihardjo I, Oliver H, Lutter M, Luo X, Wang X. Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol 1999;15:269-90.
48. Bernardi P, Petronilli V, Di Lisa F, Forte M. A mitochondrial perspective on cell death. Trends Biochem Sci 2001;26:112-7.
49. Blagosklonny MV, Schulte T, Nguyen P, Trepel J, Neckers LM. Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Res 1996;56:1851-4.
50. Yamamoto K, Ichijo H, Korsmeyer SJ. BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Mol Cell Biol 1999;19:8469-78.